Lv612
3190 积分 2024-03-15 加入
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
1天前
已完结
Nanobodies® for veterinary health: multifunctional roles in diagnostics, therapeutics, and vaccines
1个月前
已关闭
Combination therapy strategies targeting glypican-3 in hepatocellular carcinoma: A comprehensive review
1个月前
已完结
Nanobody-drug conjugates as versatile tools for improving therapeutic potential
1个月前
已关闭
Theranostic application of 131I-labeled anti-glypican-3 antibody for targeted radioimmunotherapy in hepatocellular carcinoma
1个月前
已关闭
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials
1个月前
已完结
Treatments on the Horizon for Men with Advanced Prostate Cancer
1个月前
已完结
Humanized synthetic nanobody library for antivenom development
1个月前
已关闭
Nanobody-based targeted cancer therapy and immunotherapy: fear not the future
1个月前
已完结
A rationally designed bispecific antibody targeting GPC3 and PD-L1 induces tumor-directed immune activation and cytotoxicity
1个月前
已完结
皖公网安备34019202002308
